Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. Clinical cancer research : an official journal of the American Association for Cancer Research Schneider, B. P., Shen, F., Gardner, L., Radovich, M., Li, L., Miller, K. D., Jiang, G., Lai, D., O'Neill, A., Sparano, J. A., Davidson, N. E., Cameron, D., Gradus-Pizlo, I., Mastouri, R. A., Suter, T. M., Foroud, T., Sledge, G. W. 2017; 23 (1): 43-51

Abstract

Anthracycline-induced congestive heart failure (CHF) is a rare but serious toxicity associated with this commonly employed anticancer therapy. The ability to predict which patients might be at increased risk prior to exposure would be valuable to optimally counsel risk-to-benefit ratio for each patient. Herein, we present a genome-wide approach for biomarker discovery with two validation cohorts to predict CHF from adult patients planning to receive anthracycline.We performed a genome-wide association study in 3,431 patients from the randomized phase III adjuvant breast cancer trial E5103 to identify single nucleotide polymorphism (SNP) genotypes associated with an increased risk of anthracycline-induced CHF. We further attempted candidate validation in two independent phase III adjuvant trials, E1199 and BEATRICE.When evaluating for cardiologist-adjudicated CHF, 11 SNPs had a P value <10(-5), of which nine independent chromosomal regions were associated with increased risk. Validation of the top two SNPs in E1199 revealed one SNP rs28714259 that demonstrated a borderline increased CHF risk (P = 0.04, OR = 1.9). rs28714259 was subsequently tested in BEATRICE and was significantly associated with a decreased left ventricular ejection fraction (P = 0.018, OR = 4.2).rs28714259 represents a validated SNP that is associated with anthracycline-induced CHF in three independent, phase III adjuvant breast cancer clinical trials. Clin Cancer Res; 23(1); 43-51. ©2016 AACR.

View details for DOI 10.1158/1078-0432.CCR-16-0908

View details for PubMedID 27993963

View details for PubMedCentralID PMC5215621